We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

Extended distal pancreatectomy in pancreatic cancer: is it justified? A systematic review of literature

    Sagar H Chandrashekhar

    Department of Surgical Gastroenterology, Institute of Gastroenterology Sciences & Organ Transplantation, Bengaluru, 560002, India

    ,
    Simi Ismail

    Department of Radiology, Kerala Institute of Medical Sciences, Thiruvananthapuram, 695029, India

    ,
    Pavan K Jonnada

    Department of Surgical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, 500034, India

    ,
    Baiju Senadhipan

    Department of Surgical Gastroenterology, SK Hospital, Thiruvananthapuram, 695006, India

    ,
    Monish Karunakaran

    *Author for correspondence:

    E-mail Address: monish3682@gmail.com

    Department of Surgical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, 500032, India

    College of Medicine & Public Health, Flinders University, South Australia, Australia

    &
    Savio George Barreto

    College of Medicine & Public Health, Flinders University, South Australia, Australia

    Division of Surgery & Peri-operative Medicine, Flinders Medical Center, Bedford Park, Adelaide, South Australia, 5042, Australia

    Published Online:https://doi.org/10.2217/fon-2022-1180

    Background: Extended distal pancreatectomy (EDP) is being increasingly performed for pancreatic cancers with suspected invasion into the adjacent organs. However, the perioperative safety and oncological efficacy of this procedure merit further elucidation. Methods: Major databases were searched for studies evaluating EDP, and a meta-analysis was performed using fixed- or random-effects models. Results: Fifteen studies were included in the analysis. EDP was found to be associated with significantly greater incidence of postoperative pancreatic fistula overall and with major complications, re-explorations, mortality and readmissions. However, on pooled analysis of 3- and 5-year survival, EDP was found to be noninferior to standard distal pancreatectomy. Conclusion: EDP is feasible and may offer equivalent survival in highly selected patients but carries a higher risk of perioperative morbidity and mortality.

    References

    • 1. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 18(1), 688 (2018).
    • 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
    • 3. Winer LK, Dhar VK, Wima K et al. The impact of tumor location on resection and survival for pancreatic ductal adenocarcinoma. J. Surg. Res. 239, 60–66 (2019).
    • 4. Meng R, Chen J, D'Onise K, Barreto SG. Pancreatic ductal adenocarcinoma survival in South Australia: time trends and impact of tumour location. ANZ J. Surg. 91(5), 921–926 (2021).
    • 5. Barreto S, Shukla P, Shrikhande S. Tumors of the pancreatic body and tail. World J. Oncol. 1(2), 52–65 (2010).
    • 6. Zheng Z, Wang M, Tan C et al. Disparities in survival by stage after surgery between pancreatic head and body/tail in patients with nonmetastatic pancreatic cancer. PLOS ONE 14(12), e0226726 (2019).
    • 7. Birnbaum D, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and body/tail pancreatic carcinomas are not the same tumors. Cancers 11(4), 497 (2019).
    • 8. Parikh PY, Lillemoe KD. Surgical management of pancreatic cancer – distal pancreatectomy. Semin. Oncol. 42(1), 110–122 (2015).
    • 9. Luo G, Jin K, Cheng H et al. Prognosis of distal pancreatic cancers controlled by stage. Exp. Ther. Med. 20(2), 1091–1097 (2020).
    • 10. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford) 10(5), 371–376 (2008).
    • 11. van Erning FN, Mackay TM, van der Geest LGM et al. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta Oncol. 57(12), 1655–1662 (2018).
    • 12. Toomey P, Hernandez J, Golkar F, Ross S, Luberice K, Rosemurgy A. Pancreatic adenocarcinoma: complete tumor extirpation improves survival benefit despite larger tumors for patients who undergo distal pancreatectomy and splenectomy. J. Gastrointest. Surg. 16(2), 376–381 (2012).
    • 13. Ruess DA, Makowiec F, Chikhladze S et al. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. BMC Surg. 15, 123 (2015).
    • 14. Hank T, Hinz U, Tarantino I et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br. J. Surg. 105(9), 1171–1181 (2018).
    • 15. Howard TJ, Krug JE, Yu J et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J. Gastrointest. Surg. 10(10), 1338–1345; discussion 45–46 (2006).
    • 16. Shrikhande SV, Barreto SG. Extended pancreatic resections and lymphadenectomy: an appraisal of the current evidence. World J. Gastrointest. Surg. 2(2), 39–46 (2010).
    • 17. Siripong A, Chung M, Rich SE. Multivisceral pancreatic resections: worth the risk? Clin. Surg. 3, 1–7 (2018).
    • 18. Probst P, Huttner FJ, Meydan O et al. Evidence map of pancreatic surgery – a living systematic review with meta-analyses by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 170(5), 1517–1524 (2021).
    • 19. Hartwig W, Vollmer CM, Fingerhut A et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 156(1), 1–14 (2014).
    • 20. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
    • 21. Bassi C, Marchegiani G, Dervenis C et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 161(3), 584–591 (2017).
    • 22. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240(2), 205–213 (2004).
    • 23. Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J. Gastrointest. Surg. 7(8), 946–952; discussion 52 (2003).
    • 24. Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J. Gastrointest. Surg. 9(7), 922–927 (2005).
    • 25. Irani JL, Ashley SW, Brooks DC et al. Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection. J. Gastrointest. Surg. 12(12), 2177–2182 (2008).
    • 26. Roch AM, Singh H, Turner AP et al. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. Am. J. Surg. 209(3), 564–569 (2015).
    • 27. Kleeff J, Diener MK, Z'Graggen K et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann. Surg. 245(4), 573–582 (2007).
    • 28. Malinka T, Klein F, Andreou A, Pratschke J, Bahra M. Distal pancreatectomy combined with multivisceral resection is associated with postoperative complication rates and survival comparable to those after standard procedures. J. Gastrointest. Surg. 22(9), 1549–1556 (2018).
    • 29. Seeliger H, Christians S, Angele MK et al. Risk factors for surgical complications in distal pancreatectomy. Am. J. Surg. 200(3), 311–317 (2010).
    • 30. Beetz O, Sarisin A, Kaltenborn A, Klempnauer J, Winkler M, Grannas G. Multivisceral resection for adenocarcinoma of the pancreatic body and tail – a retrospective single-center analysis. World J. Surg. Oncol. 18(1), 218 (2020).
    • 31. Goh BK, Tan YM, Cheow PC et al. Outcome of distal pancreatectomy for pancreatic adenocarcinoma. Dig. Surg. 25(1), 32–38 (2008).
    • 32. Paye F, Micelli Lupinacci R, Bachellier P, Boher JM, Delpero JR, French Surgical Association. Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment. Br. J. Surg. 102(3), 229–236 (2015).
    • 33. Panzeri F, Marchegiani G, Malleo G et al. Distal pancreatectomy associated with multivisceral resection: results from a single centre experience. Langenbecks Arch. Surg. 402(3), 457–464 (2017).
    • 34. Sahakyan MA, Kleive D, Kazaryan AM et al. Extended laparoscopic distal pancreatectomy for adenocarcinoma in the body and tail of the pancreas: a single-center experience. Langenbecks Arch. Surg. 403(8), 941–948 (2018).
    • 35. Song KB, Kwon J, Kim YW et al. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. J. Hepatobiliary Pancreat. Sci. 26(6), 227–234 (2019).
    • 36. Ramia JM, Del Rio-Martin JV, Blanco-Fernandez G et al. Distal pancreatectomy with multivisceral resection: a retrospective multicenter study – case series. Int. J. Surg. 82, 123–129 (2020).
    • 37. Sinn M, Striefler JK, Sinn BV et al. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J. Surg. Oncol. 108(6), 398–402 (2013).
    • 38. Gooiker GA, van der Geest LG, Wouters MW et al. Quality improvement of pancreatic surgery by centralization in the western part of The Netherlands. Ann. Surg. Oncol. 18(7), 1821–1829 (2011).
    • 39. Hartel M, Wente MN, Di Sebastiano P, Friess H, Buchler MW. The role of extended resection in pancreatic adenocarcinoma: is there good evidence-based justification? Pancreatology 4(6), 561–566 (2004).
    • 40. Shukla PJ, Barreto SG, Bedi M et al. Peri-operative outcomes for pancreatoduodenectomy in India: a multi-centric study. HPB (Oxford) 11(8), 638–644 (2009).
    • 41. Wittmann D, Hall WA, Christians KK et al. Impact of neoadjuvant chemoradiation on pathologic response in patients with localized pancreatic cancer. Front Oncol. 10, 460 (2020).
    • 42. Bergenfeldt M, Moesgaard F, Burcharth F. Curative resection for left-sided pancreatic malignancy. HPB (Oxford) 8(3), 211–215 (2006).
    • 43. Watanabe G, Ushida Y, Oba A et al. Impact of tumor size on the outcomes of patients with resectable distal pancreatic cancer: lessons learned from a series of 158 radical resections. Ann. Surg. Oncol. 29(1), 378–388 (2022).
    • 44. Burdelski CM, Reeh M, Bogoevski D et al. Multivisceral resections in pancreatic cancer: identification of risk factors. World J. Surg. 35(12), 2756–2763 (2011).
    • 45. Hartwig W, Hackert T, Hinz U et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann. Surg. 250(1), 81–87 (2009).
    • 46. Rosso E, Langella S, Addeo P et al. A safe technique for radical antegrade modular pancreatosplenectomy with venous resection for pancreatic cancer. J. Am. Coll. Surg. 217(5), e35–e39 (2013).
    • 47. Klompmaker S, Peters NA, van Hilst J et al. Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR): an international multicenter analysis. Ann. Surg. Oncol. 26(3), 772–781 (2019).
    • 48. Altieri MS, Yang J, Yin D, Spaniolas K, Talamini M, Pryor A. Thirty days are inadequate for assessing readmission following complex hepatopancreatobiliary procedures. Surg. Endosc. 33(8), 2508–2516 (2019).
    • 49. Karunakaran M, Barreto SG. Is enhancing recovery after pancreatic cancer surgery even possible? Chin. Clin. Oncol. 10(5), 49 (2021).
    • 50. Karunakaran M, Barreto SG, Singh MK, Kapoor D, Chaudhary A. Deviations from a clinical pathway post pancreatoduodenectomy predict 90-day unplanned re-admission. Future Oncol. 16(24), 1839–1849 (2020).
    • 51. Kwon MA. Perioperative surgical home: a new scope for future anesthesiology. Korean J. Anesthesiol. 71(3), 175–181 (2018).
    • 52. Katz MH, Slack R, Bruno M et al. Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of ‘TeleDischarge’. J. Surg. Res. 202(1), 196–203 (2016).
    • 53. de Rooij T, Tol JA, van Eijck CH et al. Outcomes of distal pancreatectomy for pancreatic ductal adenocarcinoma in The Netherlands: a nationwide retrospective analysis. Ann. Surg. Oncol. 23(2), 585–591 (2016).
    • 54. Hartwig W, Gluth A, Hinz U et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Br. J. Surg. 103(12), 1683–1694 (2016).
    • 55. Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J. Gastrointest. Surg. 6(2), 147–157; discussion 57–58 (2002).
    • 56. Gillen S, Schuster T, Friess H, Kleeff J. Palliative resections versus palliative bypass procedures in pancreatic cancer – a systematic review. Am. J. Surg. 203(4), 496–502 (2012).
    • 57. Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control. 27(1), 1073274820976593 (2020). doi: 10.1177/1073274820976593.
    • 58. Barreto SG, Kleeff J. Synchronous arterial resections in pancreatic cancer – still a matter of debate? Eur. J. Surg. Oncol. 47(2), 480–482 (2021).
    • 59. Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Chiaro MD. Neoadjuvant treatment in pancreatic cancer. Front Oncol. 10, 245 (2020). doi: 10.3389/fonc.2020.00245.